Clinical Trials
66 trialsMK-3475-01G
Merck Sharp & Dohme LLC
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Phanes Therapeutics
MK-3475-01A
Merck Sharp & Dohme LLC
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
University of Southern California
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
H. Lee Moffitt Cancer Center and Research Institute
MK-7684A-007
Merck Sharp & Dohme LLC
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Abramson Cancer Center at Penn Medicine
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
H. Lee Moffitt Cancer Center and Research Institute
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
Sun Yat-sen University
MK-3475A-D77
Merck Sharp & Dohme LLC
MK-5890-001
Merck Sharp & Dohme LLC
MK-3475A-D77
Merck Sharp & Dohme LLC
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
UNC Lineberger Comprehensive Cancer Center
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Beijing Chest Hospital, Capital Medical University
MK-3475-A86
Merck Sharp & Dohme LLC
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
KEYNOTE-407
Merck Sharp & Dohme LLC
abound2L+
Celgene
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Tang-Du Hospital
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Henan Cancer Hospital
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
Columbia University
Genetic Predictors of Benefit to Pembrolizumab
Columbia University
DURATION
AIO-Studien-gGmbH
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC
Hoosier Cancer Research Network
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
PROPEL
Nektar Therapeutics
Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC
Tang-Du Hospital
MK-3475-021
Merck Sharp & Dohme LLC
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Alliance Foundation Trials, LLC.
MK-3475-434
Merck Sharp & Dohme LLC
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
Cellectar Biosciences, Inc.
neoSCORE
Second Affiliated Hospital, School of Medicine, Zhejiang University
High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Radiation Therapy Oncology Group
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
HFHS 21-01
Henry Ford Health System
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer
GU Research Network, LLC
NEPTUN
iOMEDICO AG
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
University of Washington
MK-3475-011
Merck Sharp & Dohme LLC
NeoTAP01
Sun Yat-sen University
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
Sichuan Cancer Hospital and Research Institute
N3
Royal Marsden NHS Foundation Trust
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Eli Lilly and Company
Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
University of Pittsburgh
Single Arm on the Tolerability of Weekly Nab-paclitaxel
UNC Lineberger Comprehensive Cancer Center
Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer
Celgene